首页 >>2016年02期
乙型肝炎病毒母婴阻断研究进展及对策
作者:贾涛 王锐

摘要:

母婴垂直传播是乙型肝炎的主要传播方式,是造成高流行地区慢性乙型肝炎病毒(HBV)感染率较高的主要原因。因此,预防乙型肝炎的母婴传播,可从根本上降低人群的慢性HBV携带率。接种乙型肝炎疫苗是目前最经济、有效和安全的预防HBV母婴的措施。今后预防母婴传播的重点应是加强孕产妇的HBV表面抗原筛查,对HBV表面抗原阳性孕妇所生新生儿联合接种高效价乙肝免疫球蛋白,并进行免疫后的监测,科学评估母婴阻断的实施效果。

关键词:肝炎,乙型;接种;母婴传播

Abstract:

Mother-to-child transmission (MTCT) is the main way to transmit hepatitis B virus (HBV), and it is also the biggest contributor to high prevalence of hepatitis B in high endemic areas. Therefore, preventing MTCT may result in the decline of HBV positive ratio foundationally. Hepatitis B vaccination is currently recognized as the most economic, effective and safe measure to prevent MTCT. The key strategies in the future to prevent MTCT should be to enhance the screening of hepatitis B surface antigen, to provide the infants born to surface antigen positive mother with hepatitis B vaccine combine with hepatitis B immunoglobulin(HBIG), and to monitor the effect of the intervention.

Key words: Hepatitis B;Vaccination;Mother to child transmission

发表日期:2016/2

引用本文:

图/表:

    暂无图表

参考文献:

[1]XiaG, LiuC, CaoH, et al. Prevalence of hepatitis B and C virus infections in the general Chinese population. Results from a nationwide cross-sectional seroepidemiologic study of hepatitis A, B, C, D and E virus infections in China, 1992[J]. International Hepatology Communications, 1996, 5(1): 62-73.
[2]郑徽,崔富强,龚晓红,等.我国育龄期妇女乙型肝炎病毒表面抗原及e抗原流行现状分析[J].中国疫苗和免疫,2010,16(6):496-499.
[3]XuH, ZengT, LiuJY, et al. Measures to reduce mother-to-child transmission of Hepatitis B virus in China: a meta-analysis[J]. Dig Dis Sci, 2014, 59(2): 242-58. Doi: 10.1007/s10620-013-2918-0.
[4]NguyenLH, NguyenMH. Prevention of mother-to-child transmission of hepatitis B virus: is elective cesarean section in highly viremic mothers an appropriate adjunct to immunoprophylaxis?[J]. Clin Gastroenterol Hepatol, 2013, 11(10): 1356-1357. Doi: 10.1016/j.cgh.2013.04.017.
[5]Kowalik-MikolajewskaB, AniszewskaM, Pokorska-SpiewakM. Mother-to-child HBV transmission--atypical course of hepatitis B in an infant[J]. Med Wieku Rozwoj, 2012, 16(2): 149-153.
[6]郝红晓,张璐,李明慧,等.影响HBV母婴阻断效果的相关因素研究进展[J].中华实验和临床病毒学杂志,2015,29(1):93-94.Doi: 10.3760/cma.j.issn.1003-9279.2015.01.031.
[7]NiYH. Natural history of hepatitis B virus infection: pediatric perspective[J]. J Gastroenterol, 2011, 46(1): 1-8. Doi: 10.1007/s00535-010-0304-7.
[8]OnakewhorJU, OlagbujiBN, OkpereEE. Pattern and risk factors for partner infection with hepatitis B virus in a prevention of mother-to-child transmission programme[J]. West Afr J Med, 2013, 32(2): 110-114.
[9]WHO advisory committee on immunization and vaccine related implementation research (IVIR, formerly QUIVER): executive summary report of 7th meeting[J]. Wkly Epidemiol Rec, 2013, 88(44/45): 486-488.
[10]张雪妍,王跃锜,周永康,等.国内儿童预防接种乙肝疫苗安全性Meta分析[J].现代预防医学,2015,42(9):1611-1617.
[11]颜天强,王继杰,龙智钢,等.国产重组酵母乙肝疫苗新生儿接种后安全性及免疫效果研究[J].实用预防医学,2000,7(5):340-342. DOI: 10.3969/j.issn.1006-3110.2000.05.009.
[12]邵晓萍,吴承刚,王富珍,等.2013年广东省三个县1~14岁儿童乙型肝炎血清流行病学调查分析[J].中华预防医学杂志,2015,49(9):777-781. DOI: 10.3760/cma.j.issn.0253-9624.2015.09.004.
[13]缪宁,张国民,郑徽,等.2013年中国乙型肝炎监测试点数据分析[J].中华预防医学杂志,2015,49(9):766-770. DOI: 10.3760/cma.j.issn.0253-9624.2015.09.002.
[14]崔富强,王富珍,郑徽,等.接种不同剂量重组乙型肝炎疫苗(酵母)阻断乙型肝炎病毒母婴传播的评价[J].中国计划免疫,2007,13(4):289-292. DOI: 10.3969/j.issn.1006-916X.2007.04.001.
[15]孙莲英,庞志钊,张文英,等.不同剂量重组乙型肝炎疫苗(酵母)阻断乙型肝炎病毒母婴传播的研究[J].中国计划免疫,2006,12(4):262-263. DOI: 10.3969/j.issn.1006-916X.2006.04.006.
[16]夏国良,贾志远,颜天强,等.新生儿单纯乙型肝炎血源疫苗的免疫持久性和远期保护效果[J].中华实验和临床病毒学杂,2002,16(2):146-149. DOI: 10.3760/cma.j.issn.1003-9279.2002.02.010.
[17]李荣成,龚健,杨进业,等.乙型肝炎疫苗长期免疫效果的研究[J].广西预防医学,2002,8(5):257-261. DOI: 10.3969/j.issn.1673-758X.2002.05.001.
[18]沈立萍,龚晓红,王锋,等.乙型肝炎疫苗长期免疫效果评价及免疫持久性研究[J].中华微生物学和免疫学杂志,2013,33(1):6-10. DOI: 10.3760/cma.j.issn.0254-5101.2013.01.004.
[19]李伟,张薇莉,赵隽.联合免疫阻断乙肝病毒母婴传播的效果观察和失败原因分析[J].中国医刊,2014(9):81-83. DOI: 10.3969/j.issn.1008-1070.2014.09.028.
[20]王富珍,崔富强,郑徽,等.重组乙型肝炎疫苗(酵母)与乙型肝炎免疫球蛋白联合免疫阻断乙型肝炎病毒母婴传播的效果分析[J].中国计划免疫,2007,13(4):293-297. DOI: 10.3969/j.issn.1006-916X.2007.04.002.
[21]谢若欣,杨洁芳,霍乐颍.不同剂量乙肝免疫球蛋白联合乙肝疫苗阻断乙肝病毒母婴传播的疗效比较[J].中国临床新医学,2015,8(8):754-757. DOI: 10.3969/j.issn.1674-3806.2015.08.16.
[22]朱宝中,黄卫平,李素文,等.不同剂量乙肝疫苗与HBIG联合免疫阻断HBV母婴传播的效果对比[J].中华实验和临床病毒学杂志,2014,28(6):449-451. DOI: 10.3760/cma.j.issn.1003-9279.2014.06.016.
[23]邹怀宾,陈煜,张华,等.乙型肝炎病毒母婴传播及其阻断研究的现状与存在问题[J].中华肝脏病杂志,2010,18(7):556-558. DOI: 10.3760/cma.j.issn.1007-3418.2010.07.026.
[24]K?seS, TürkenM, DevrimI, et al. Efficacy and safety of lamivudine treatment in late pregnancy with high HBV DNA: a perspective for mother and infants[J]. J Infect Dev Ctries, 2011, 5(4): 303-306.
[25]XuWM, CuiYT, WangL, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study[J]. J Viral Hepatitis, 2009, 16(2): 94-103. Doi: 10.1111/j.1365-2893.2008.01056.x.
[26]白兴武,王晓斌,李建团,等.不同母婴阻断方式对新生儿乙型肝炎病毒母婴传播的影响[J].中国妇幼保健,2011,26(21):3265-3266.
[27]杨会英,宁淑敏,张玉荣,等.HBIG联合替比夫定阻断HBV母婴传播的作用分析[J].中国妇幼保健,2015,30(4):542-543.
[28]ZhuQ, YuG, YuH, et al. A randomized controlled trial on interruption of HBV transmission in utems[J]. Chin Med J (Engl), 2003, 116(5): 685-687.
[29]YuanJ, LinJ, XuA, et al. Antepartum immoprophylaxis of three doses of hepatitis B immunoglobulin is not effective: a single center randomized study[J]. J Viral Hepat, 2006, 13(9): 597-604.
[30]雷正龙,崔富强.有计划的预防接种是提高国民健康水平的重要保障[J].中华预防医学杂志,2014,48(6):433-436. DOI: 10.3760/cma.j.issn.0253-9624.2014.06.001.
[31]鲁凤民,李杰.关于核苷类似物用于阻断妊娠晚期母婴传播的讨论意见[J].肝脏,2011,16(2):167. DOI: 10.3969/j.issn.1008-1704.2011.02.029.
[32]唐中权,郭艳.HBV宫内感染母婴阻断的临床进展[J].中华实验和临床感染病杂志,2013,7(3):461-462. DOI: 10.3877/cma.j.issn.1674-1358.2013.03.034.

用户评论 0条

用户名: 密码: 登陆 注册
 
  • 9
  • 3
  •  4 : 页次:0/0页 共0条记录 5条/每页
    关于我们 | 专家风采 | 会员注册 | 继续教育
    地 址:北京市西城区东河沿街69号正弘大厦511室 邮 编:100052
    电话:010-51322302
    版权所有 中华医学会及中华预防医学杂志编辑部
    京ICP备 07035254 号